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Laboratory properties of cold-adapted 
influenza B live vaccine strains 
developed in the US and USSR, and 
their B/Ann Arbor/i/86 cold-adapted 
reassortant vaccine candidates 
G.I. Alexandrova*, H.F. Maassab t, A.P. Kendal ++, T.E. Medvedeva* 
A.Y. Egorov*, A.I. Klimov § and N.J. Cox ~; 
The adaptation of  two influenza B strains (B/Leningrad]14/55 and B[Ann Arbor/I/66) to 
replication at 25°C is described. Comparison of  the two viruses indicates that both also exhibit 
temperature sensitive phenotypes, although that o f  the virus B/Leningrad/14/55 is less pronounced. 
When inoculated into ferrets both viruses replicate well in the trachea, but only the 
B/ Leningrad]14155 cold-adapted virus replicates in the lungs. This virus exhibited a moderate level 
of  attenuation in the animals, in contrast to the B/Ann Arbor/l/66 cold-adapted virus, which was 
fully attenuated. Reassortant viruses deriving the surface antigens of  the contemporary wild type 
virus B/Ann Arbor/l/86 and most or all o f  their other genes, from o n e  o r  other cold-adapted 
parent, were virtually indistinguishable from their respective cold-adapted parents. The 
B/Leningrad/14/55 reassortant was slightly more attenuated than its coid-adapted parent in ferrets. 
These studies extend knowledge of  the properties o f  viruses used to prepare experimental live 
influenza B human vaccines. 
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Introduction 
A recent method for preparation of attenuated vaccine 
strains of influenza virus is based on the recombination 
of contemporary wild-type (wt) viruses with a cold- 
adapted (ca) donor strain. Reassortant viruses which 
inherit the genes coding for haemagglutinin and neura- 
minidase from the epidemic virus and most of the other 
genes from the ca donor strain are then selected by 
antigenic and molecular analysis 1-3. 
Most studies to date with reassortant ca influenza 
viruses have involved type A strains. The progress with 
the techniques used has prompted us to extend these 
procedures to type B influenza vaccine. Presently, the 
following ca type B influenza strains exist: B/Leningrad/ 
14/55, B/USSR/69/60, B/Dushanbe/62 and B/USSR/67, 
developed in the USSR (Ref. 4 and unpublished 
results), and B/Massachussetts/66, B/Ann Arbor/I/66 
and B/Tecumseh/1/69 developed in the US 5. Although 
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these viruses have been available for several years, only 
recently have reassortants begun to be prepared from 
them for laboratory and clinical analysis. 
In 1985/86 major epidemics of influenza B occurred in 
some countries, including Eastern Europe and the US, 
in association with high levels of morbidity in children 
and adults 6'7. The epidemic was caused by a new 
antigenic variant, for which the reference strain B/Ann 
Arbor/I/86 was selected for production of the subsequent 
inactivated vaccine s . This opportunity was taken simul- 
taneously to prepare ca reassortant viruses from candidate 
ca vaccine strains in the US and USSR, and the same 
wt reference strain, for comparison of their properties. 
Such a comparison of laboratory properties is described 
here, with clinical evaluation of the reassortant derived 
in the USSR described elsewhere 9. 
Materials and methods 
Viruses 
The wt B/Ann Arbor/I/86 strain was isolated during 
thc 1985/86 epidemic in the US. Virus was isolated in 
specific pathogen free (SPF) eggs, during a single passage, 
then plaque-purified twice at a temperature of 37°C in 
primary chick kidney cells (PCKC) prepared from SPF 
embryos, and finally passaged twice more in SPF eggs 
to prepare a seed pool uscd as the starting material for 
preparation of candidate vaccines. The B/Leningrad/14/55 
strain was isolated from an ill child in 1955; it had 
undergone 20 passages in embryonated eggs at a 
temperature of 32°C beforc being adapted to grow at the 
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normally sub-optimal temperature of 25°C by 17 
passages in embryonated eggs at 25-26°C 4'L°. Derivation 
of the B/Ann Arbor/I /66 ca virus was by passage in 
PCKC at successively lower temperatures. Including 
initial isolation, the virus had received seven PCK 
passages before being considered adapted to growth at 
25°C 5. This was plaque-purified by seven sequential 
passages in PCKC from SPF embryos, before preparing 
an egg pool for use in the studies described. 
Preparation of  ca reassortant viruses 
For preparation of a reassortant virus with the ca 
B/Leningrad/14/55 parent, virulent B/Ann Arbor/I/86 
virus (at a dose of 6.25 loglo EIDso/0.2 ml) was partially 
inactivated by heating (at 36°C for 48h), reducing its 
infectivity by 3.75 logs. This preparation was mixed with 
an equal volume of untreated ca B/Leningrad/14/55 
virus, containing 6.25 logs of infectivity. Chick embryos 
were infected with a mixture of the viruses and incubated 
at 34°C for 48 h. The reassortant was selected after two 
passages in the presence of 16-32 neutralizing units of 
antiserum to the B/Leningrad/14/55 virus followed by 
cloning in embryonated eggs at 34°C for 72h using 
limited dilution technique. Clones were then selected with 
antigenic characteristics of the B/Ann Arbor/I/86 virus, 
and their genome composition screened as described 
below. A clone designated LEN-B/14/5/1 was used for 
subsequent studies, after verification it contained only 
the HA, NA and NS genes from the wild-type parent. 
Derivation of the reassortant of wt B/Ann Arbor/I/86 
and ca B/Ann Arbor/I/66 was accomplished by mixed 
infection of PCKC at 25°C, and selection in the presence 
of immune serum to B/Ann Arbor/I/86, as previously 
described for influenza A viruses 1. After two cycles of 
plaque purification at 25°C, genome composition of 
reassortant viruses was determined as described below, 
and the clone designated AA-CRB117 selected for further 
studies. This reassortant contained only HA and NA of 
the wt parent virus.. 
Effect of temperature on replication. Cold-adaptation 
and temperature sensitivity were determined by either 
titration in embryonated eggs or PCKC cultures at 25°C, 
32°-34°C, and 37°C, 38°C or 39°C, as previously 
described ~l'~z. End points were determined as either 
median egg infectious doses (EIDso) or, in the case of 
tissue culture, p.f.u, ml -  
Animal studies. The ability of the parental and 
reassortant viruses to replicate in the upper and lower 
respiratory tracts of ferrets was determined as previously 
described ~ 3. 
Genome analysis. Electrophoresis of single-stranded 
virion RNA was performed for both the LEN-B/14/5/1 
and AA-CRB/117 reassortant viruses, and their respective 
Table 1 Change of phenotype of B/Leningrad/14/55 after cold- 
adaptation 
No. of egg passages 
Ioglo p.f.u, ml -~ 
in chick kidney cells 
32°C 25°C Total 25°C 32°C 38°C 
20 0 20 3.5 6.4 3.2 
20 17 37 5.9 6.8 0 
Table 2 Adaptation of influenza B/Ann Arbor/I/66 to growth at 25°C in 
primary chick kidney cells (PCKC)' 
No. of passages 





33°C 30°C 27°C 25°C (p.f.u. m1-1) 
2 2 1 1 3 x  10' 
aB/Ann Arbor/ l /66 originally isolated in PCKC 
Table 3 Comparison of ca influenza B viruses for replication at different 
temperatures in primary chick kidney cells (PCKC) 
Infectivity titre (p.f.u. m1-1) in PCKC 
25°C 33°C 3T'C 39°C 
Parental viruses 
wt B/Ann Arbor / l /86  < 103 7 x 10 s 5 x 10 ° < 10" 
ca BILeningrad114155 1 x 10" 2 x 10" 8 x 10' < 10" 
ca B/Ann Arbor / I /66  1 x 10 a 3 x 10 s <103 N.D. 
Reassortant viruses 
LEN-B/14/5/1 9 x 107 2 x 107 4 x 107 < 10" 
AA-CRB117 2x107 5x107 <103 N.D. 
parents, as previously described 14"15. In addition, the 
technique of cRNA:vRNA hybridization followed by 
electrophoresis of nuclease S 1-treated homologous and 
heterologous double stranded RNA's 16'17 was used to 
confirm results with the reassortant LEN-B-14/5/I. 
Results 
Cold-adaptation and ts phenotypes of  parental 
viruses 
Virus B/Leningrad/14/55 was sequentially passaged 20 
times in embryonated eggs at 32°C and then 17 times at 
25°C to yield the modified virus designated B/Leningrad/ 
14/17/55. This  virus could be differentiated from its 
progenitor in having higher levels of replication at 25°C, 
and lower replication at 38°C in PCKC (Table 1). The 
virus B/Ann Arbor/I/66 was passaged at sequentially 
lower temperatures in PCKC until the derived ca virus 
replicated efficiently at 25°C (Table 2). 
When the ca viruses derived in the US and USSR were 
compared, they were equally adapted to growth at 25°C 
(Table 3). However, in these studies, which utilized 
temperatures of 37°C and 39°C to detect temperature 
sensitivity, only the B/Ann Arbor ca virus experienced a 
cut-off in replication at a lower temperature than the wt 
B/Ann Arbor/I/86 included as a control. Thus, it appears 
probable that the degree of temperature sensitivity of 
the ca B/Leningrad/14/17/55 virus is somewhat less 
pronounced than for the ca B/Ann Arbor/I/66 virus. 
Cold-adaptation and ts phenotypes of  
reassortant viruses 
Comparison of the replication in PCKC of parental 
and ca reassortant viruses at different temperatures 
indicated that the LEN-B/14/5/1 reassortant virus was 
indistinguishable from its B/Leningrad/14/17/55 ca parent, 
and the AA-CRB117 virus was indistinguishable from its 
B/Ann Arbor/I/66 ca parent (Table 3). Thus, both ca 
reassortants replicated much better than their contem- 
porary wt parent B/Ann Arbor/I/86 at 25°C, whereas 
only the AA-CRBlt7 virus, but not the LEN-B/14/5/1 
virus, was restricted in replication at 37°C. 
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Tab le4  Replication of ca B/Leningrad/14/55 virus and its c.a. 
reassortant LEN-B/14/5/1 in embryonated eggs at different temperatures 
Titre (IoglQ. EIDso ) 
Virus 25°C 34°C 37 °C 38 °C 
wt B/Ann Arbor / l /86  2.25 7.25 6.25 1.25 
ca B/Leningrad/14/17/55 6.0 7.5 7.0 1.0 
ca LEN-B/14/5/1 6.5 8.5 7.75 2.5 
Titration of the Leningrad viruses in embryonated eggs 
confirmed the cold-adaptation phenotype of the parental 
and reassortant ca viruses (Table 4). In this host system, 
as in PCKC, temperature sensitivity was not detected at 
37°C for the ca Leningrad parent or reassortant. Because 
even wt influenza B virus does not replicate reliably in 
eggs at 38°C no meaningful evidence of ts phenotype 
could be obtained from the ca B/Leningrad viruses in 
eggs. Egg infectivity titrations at different temperatures 
were not carried out for the B/Ann Arbor/I/66 ca virus, 
or its ca reassortant. Clone LEN-B/14/5/I was passed in 
eggs at 34°C five times to determine the possible 
alteration in ca phenotype. Titration in eggs after the 
fifth passage showed no changes (not shown). 
Replication in ferrets 
In two experiments a total of four ferrets each were 
infected in parallel with wt virus B/Ann Arbor/I/86, 
ca parental viruses B/Leningrad/14/17/55 and B/Ann 
Arbor/I/66, and the ca reassortant viruses LEN-B/14/5/1 
and AA-CRBll7.  The wt contemporary virus B/Ann 
Arbor/I/86 was detected in both trachea and lungs at 3 
days postinfection, with lung titres being about 2 logs 
less than in the trachea (Table 5). 
Infection was associated with fever lasting 2 days in 
all animals. The cold-adapted B/Leningrad/14/17/55 
virus replicated in lungs to a titre about 2 logs lower 
than in the trachea. Only two of four ferrets experienced 
fever, of one day duration in both cases. 
Reassortant ca virus LEN-B/14/5/1 differed from both 
parent viruses in replicating only in trachea, not lungs. 
Two of four ferrets experienced low level fever of 39.9°C, 
a borderline increase compared with the normal baseline 
of 39.7°C for ferrets. Thus the reassortant LEN-B14/5/1 
appeared to be closer to having full attenuation than its 
ca parent, although evidence of marginal pathogenicity 
was evident in this animal model. 
Neither the ca B/Ann Arbor/I /66 parent virus, nor its 
reassortant AA-CRB117, replicated to detectable levels 
in ferret lungs, despite quite high levels of replication in 
trachea. Likewise, neither of these two viruses elicited 
evidence of febrile reaction, or coryza. Thus, both were 
highly attenuated. 
Discussion 
Live influenza B vaccines were used in the USSR for 
many years, and cold-adapted influenza B vaccine was 
developed by 1965 ~°'11. However, relatively little infor- 
mation exists about such vaccines, and most vaccine 
development and research has focused on influenza A. 
Although one reason for this may be the perception 
that influenza B poses a lower risk than influenza A, 
beginning in 1979 influenza B has been responsible for 
quite major epidemics, involving high risk adults, as well 
as children. Excess mortality has been consistently 
evident ~8'19. In addition, the use of inactivated influenza 
B vaccine may on many occasions provide inadequate 
protection, particularly in the elderly z°'21. This may be 
due to low immunogenicity of influenza B vaccine 21'zz, 
or the failure to include the optimum virus strain in the 
vaccine on account of virus genetic and antigenic 
heterogeneity, and the rapid spread of new variants 23. 
The availability of live attenuated influenza B vaccine 
might contribute to improved ability to control this 
disease, at least in some segments of the population. This 
would particularly be so, were such a vaccine to offer 
broader or more long-lasting immunity than inactivated 
vaccine, as has been hoped for in the case of type A virus. 
This report indicates that in theory it is possible to 
prepare new vaccinal strains containing contemporary 
surface antigens, by reassortment with ca parental virus. 
The biological marker of cold-adaptation was repro- 
ducibly transferred to reassortants, as was the ts 
phenotype if the appropriate host system was used for 
its detection. Ferret virulence was also reproducibly 
transferred in the case of the B/Ann Arbor/I/66 virus, 
but for the B/Leningrad/14/55 virus the modest residual 
virulence in the ca parent was reduced slightly further in 
its reassortant. 
Based on the in vitro and animal model data, it might 
be expected that the B/Ann Arbor/i /66 ca virus would 
prove more acceptable as a donor strain for making live 
vaccines, in view of its slightly higher temperature 
sensitivity, and lower levels of replication in ferret lungs 
than the B/Leningrad/14/55 virus. 
Unfortunately, it is still not possible to extrapolate 
directly from in vitro or animal studies to human 
clinical experience. For  example the reassortant vaccine 
LEN-B/14/5/1 was in fact highly attenuated 9. Clinical 
studies are being undertaken in the US with the B/Ann 
Arbor reassortant virus. 
Considerably more laboratory and clinical experience 
is needed before it will be known how reproducibly live 
attenuated influenza vaccines can be prepared, and their 
general efficacy determined. The only reported field study 
of efficacy in a natural challenge indicated some beneficial 
effect from a ca vaccine, but the virus was of a different 
origin from that studied here 24. Small scale volunteer 
studies with a ca reassortant of B/Ann Arbor/I/66 did 
demonstrate safety and immunogenicity, as well as 
efficacy against artificial challenge with a wt strain z5"26. 
It will also be necessary to evaluate the ability to combine 
influenza B with one or more type A components without 
interference occurring, or dilution of the type B virus 
below its infectious threshold in man. Finally, genetic 
stability must be established. The availability now of data 
on the genome sequence of at least the B/Ann Arbor/I/66 
vaccine candidate, and preliminary data on gene 
constellations associated with attenuation, will assist this 
process 27,28. 
In conclusion, the data obtained support from the 
theoretical concept that live attenuated influenza B 
vaccines can be readily obtained by reassortment with 
cold-adapted parents, including the transfer of defined 
laboratory markers. Such vaccines warrant further 
evaluation of their practical application in man. 
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